Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 29/11/2020
SIETES contiene 93175 citas

 
 
 1 a 20 de 98 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
2.Enlace a cita original Cita con resumen
Abrahami D, Douros A, Yin H, Yu OHY, Renoux C, Bitton A, Azoulay L. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018;360:21 de marzo. [Ref.ID 102562]
3. Cita con resumen
Anónimo. Drugs for type 2 diabetes. Med Lett Drugs Ther 2017;59:9-18. [Ref.ID 101372]
4. Cita con resumen
Anónimo. Diarrhées d'origine médicamenteuse. Prescrire 2016;36:748-55. [Ref.ID 100894]
5. Cita con resumen
Anónimo. Pamplemousses: des interactions avec les médicaments. Prescrire 2012;32:674-9. [Ref.ID 93661]
6. Cita con resumen
Anónimo. Inhibiteurs des alphaglucosidases intestinales: kystes gazeux abdominaux. Prescrire 2012;32:359-60. [Ref.ID 92811]
7.
Tahrani AA, Bailey C, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011;378:182-97. [Ref.ID 90871]
8.Enlace a cita original Cita con resumen
Gross J, Kramer CK, Leltao CB, Hawkins N, Viana LV, Schaan VD, Pinto LC, Rodriguez TC, Azevedo MJ. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011;154:672-9. [Ref.ID 90729]
9.Tiene citas relacionadas
Wilding JPH, Hardy K. Glucagon-like peptide-1 analogues for type 2 diabetes. BMJ 2011;342:433-6. [Ref.ID 90230]
10. Cita con resumen
Anónimo. Digoxine: gare aux interactions médicamenteuses graves. Prescrire 2009;29:908-11. [Ref.ID 87340]
11.Tiene citas relacionadas Cita con resumen
Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-72. [Ref.ID 85922]
12.Tiene citas relacionadas
Tamborlane WV, Beck RW. Continuous glucose monitoring in type 1 diabetes mellitus. Lancet 2009;373:1744-6. [Ref.ID 85912]
13.Tiene citas relacionadas
Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K, on behalf of the Voglibose Ph-2 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607-14. [Ref.ID 85803]
14.Tiene citas relacionadas Cita con resumen
Scheen AJ. Voglibose for prevention of type 2 diabetes mellitus. Lancet 2009;373:1579-80. [Ref.ID 85802]
16. Cita con resumen
Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-94. [Ref.ID 84326]
17.
Anónimo. Hypoglycémies d'origine médicamenteuse. Prescrire 2008;28:665-70. [Ref.ID 83947]
18. Cita con resumen
Anónimo. Bayer anticipates single digit growth in 2008. Scrip 2008;3341:9. [Ref.ID 82321]
19.Tiene citas relacionadas
Pogach LM. "Doctor, how CERTain are we that this diabetes medication is best for me?". Ann Intern Med 2007;147:428-30. [Ref.ID 81107]
20.Tiene citas relacionadas
Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1C targets. A guidance statement from the American College of Physicians. Ann Intern Med 2007;147:417-22. [Ref.ID 81106]
Seleccionar todas
 
 1 a 20 de 98 siguiente >>